HIV-1 vaccine design through minimizing envelope metastability
L. He, S. Kumar, J. J. Allen, D. Huang, X. Lin, C. J. Mann, K. L. Saye-Francisco, J. Copps, A. Sarkar, G. S. Blizard, G. Ozorowski, D. Sok, M. Crispin, A. B. Ward, D. Nemazee, D. R. Burton, I. A. Wilson, J. Zhu
Abstract
Overcoming envelope metastability is crucial to trimer-based HIV-1 vaccine design. Here, we present a coherent vaccine strategy by minimizing metastability. For ten strains across five clades, we demonstrate that gp41 ectodomain (gp41ECTO) is the main source of envelope metastability by replacing wild-type gp41ECTO with BG505 gp41ECTO of the uncleaved prefusion-optimized (UFO) design. These gp41ECTO-swapped trimers can be produced in CHO cells with high yield and high purity. Crystal structure of a gp41ECTO-swapped trimer elucidates how a neutralization-resistant tier 3 virus evades antibody recognition of the V2 apex. UFO trimers of transmitted/founder (T/F) viruses and UFO trimers containing a consensus-based ancestral gp41ECTO suggest an evolutionary root of the metastability. Gp41ECTO-stabilized trimers can be readily displayed on 24- and 60-meric nanoparticles, with incorporation of additional T cell help illustrated for a hyperstable 60-mer. In mice and rabbits, gp140 nanoparticles induced more effective tier 2 neutralizing antibody response than trimers with statistical significance.\n\nHIGHLIGHTSO_LIgp41 is the main source of HIV-1 envelope metastability\nC_LIO_LIBG505 gp41 of the UFO design stabilizes gp140 trimers of diverse subtypes\nC_LIO_LIgp41 stabilization facilitates gp140 nanoparticle assembly and improves production\nC_LIO_LINanoparticles elicit tier 2 neutralizing antibodies more effectively than trimers\nC_LI
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Design and immunogenicity of an HIV-1 clade C pediatric envelope glycoprotein stabilized by multiple platforms
Sanjeev Kumar, Iván del Moral-Sánchez, … Kalpana Luthra·VaccinesPeer-reviewed·Jan 22, 2025
- Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimers as HIV-1 vaccine candidates
Y.-N. Zhang, J. Paynter, … J. Zhu·bioRxiv·Jul 1, 2022
- Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens
J. M. Binley, E. Crooks, … L. Verkoczy·bioRxiv·Jul 20, 2021
- Structure-guided stabilization improves the ability of the HIV-1 gp41 hydrophobic pocket to elicit neutralizing antibodies
T. U. J. Bruun, S. Tang, … P. S. Kim·bioRxiv·Dec 22, 2022
- Immunogenicity and Structure of a Stabilized HIV -1 clade C Env from a Pediatric Elite neutralizer in Complex with an Autologous bnAb
Swarandeep Singh, Sanjeev Kumar, … Kalpana Luthra·bioRxiv·Apr 26, 2025
- Neutralizing antibodies induced by first-generation gp41-stabilized HIV-1 envelope trimers and nanoparticles